Psychiatric and behavioural disorders in children with epilepsy (ILAE Task Force Report): When should pharmacotherapy for psychiatric/behavioural disorders in children with epilepsy be prescribed?

Frank Besag, Albert Aldenkamp, Rochelle Caplan, David Dunn, Giuseppe Gobbi, Matti Sillanpää

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The most important factor in deciding whether psychotropic medication should be prescribed is a meticulous assessment of the possible causes of the behavioural/psychiatric disturbance. This assessment should include a consideration of the possible roles of the epilepsy itself, treatment of the epilepsy, associated brain damage or dysfunction, reactions to the epilepsy and causes that are unrelated to the epilepsy or its treatment. If the epilepsy itself or antiepileptic drug treatment are responsible for the disorder then a review of antiepileptic medication is required. Contrary to popular myth, most psychotropic medications are not contraindicated in children with epilepsy. Treatment with methylphenidate, dexamfetamine, atomoxetine, clonidine or low-dose risperidone are unlikely to precipitate seizures. The selective serotonin reuptake inhibitors might protect against seizures but some of these are powerful enzyme inhibitors, implying that careful monitoring to avoid antiepileptic drug toxicity is recommended. In many cases, the appropriate approach will be through other interventions such as behavioural management or providing the young person with empowering strategies, implying that psychotropic pharmacotherapy should not be the first-line treatment. However, if assessment indicates that psychotropic medication is necessary, it can be of great benefit.

Original languageEnglish (US)
Pages (from-to)S77-S86
JournalEpileptic Disorders
Volume18
StatePublished - May 1 2016

Fingerprint

Advisory Committees
Psychiatry
Epilepsy
Drug Therapy
Anticonvulsants
Seizures
Therapeutics
Dextroamphetamine
Methylphenidate
Risperidone
Serotonin Uptake Inhibitors
Clonidine
Enzyme Inhibitors
Drug-Related Side Effects and Adverse Reactions
Brain

Keywords

  • Absence
  • Anxiety
  • CSWS
  • Depression
  • Postictal

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Psychiatric and behavioural disorders in children with epilepsy (ILAE Task Force Report) : When should pharmacotherapy for psychiatric/behavioural disorders in children with epilepsy be prescribed? / Besag, Frank; Aldenkamp, Albert; Caplan, Rochelle; Dunn, David; Gobbi, Giuseppe; Sillanpää, Matti.

In: Epileptic Disorders, Vol. 18, 01.05.2016, p. S77-S86.

Research output: Contribution to journalArticle

@article{ea235bddbec04551b911d8e38e9f1c38,
title = "Psychiatric and behavioural disorders in children with epilepsy (ILAE Task Force Report): When should pharmacotherapy for psychiatric/behavioural disorders in children with epilepsy be prescribed?",
abstract = "The most important factor in deciding whether psychotropic medication should be prescribed is a meticulous assessment of the possible causes of the behavioural/psychiatric disturbance. This assessment should include a consideration of the possible roles of the epilepsy itself, treatment of the epilepsy, associated brain damage or dysfunction, reactions to the epilepsy and causes that are unrelated to the epilepsy or its treatment. If the epilepsy itself or antiepileptic drug treatment are responsible for the disorder then a review of antiepileptic medication is required. Contrary to popular myth, most psychotropic medications are not contraindicated in children with epilepsy. Treatment with methylphenidate, dexamfetamine, atomoxetine, clonidine or low-dose risperidone are unlikely to precipitate seizures. The selective serotonin reuptake inhibitors might protect against seizures but some of these are powerful enzyme inhibitors, implying that careful monitoring to avoid antiepileptic drug toxicity is recommended. In many cases, the appropriate approach will be through other interventions such as behavioural management or providing the young person with empowering strategies, implying that psychotropic pharmacotherapy should not be the first-line treatment. However, if assessment indicates that psychotropic medication is necessary, it can be of great benefit.",
keywords = "Absence, Anxiety, CSWS, Depression, Postictal",
author = "Frank Besag and Albert Aldenkamp and Rochelle Caplan and David Dunn and Giuseppe Gobbi and Matti Sillanp{\"a}{\"a}",
year = "2016",
month = "5",
day = "1",
language = "English (US)",
volume = "18",
pages = "S77--S86",
journal = "Epileptic Disorders",
issn = "1294-9361",
publisher = "Springer Paris",

}

TY - JOUR

T1 - Psychiatric and behavioural disorders in children with epilepsy (ILAE Task Force Report)

T2 - When should pharmacotherapy for psychiatric/behavioural disorders in children with epilepsy be prescribed?

AU - Besag, Frank

AU - Aldenkamp, Albert

AU - Caplan, Rochelle

AU - Dunn, David

AU - Gobbi, Giuseppe

AU - Sillanpää, Matti

PY - 2016/5/1

Y1 - 2016/5/1

N2 - The most important factor in deciding whether psychotropic medication should be prescribed is a meticulous assessment of the possible causes of the behavioural/psychiatric disturbance. This assessment should include a consideration of the possible roles of the epilepsy itself, treatment of the epilepsy, associated brain damage or dysfunction, reactions to the epilepsy and causes that are unrelated to the epilepsy or its treatment. If the epilepsy itself or antiepileptic drug treatment are responsible for the disorder then a review of antiepileptic medication is required. Contrary to popular myth, most psychotropic medications are not contraindicated in children with epilepsy. Treatment with methylphenidate, dexamfetamine, atomoxetine, clonidine or low-dose risperidone are unlikely to precipitate seizures. The selective serotonin reuptake inhibitors might protect against seizures but some of these are powerful enzyme inhibitors, implying that careful monitoring to avoid antiepileptic drug toxicity is recommended. In many cases, the appropriate approach will be through other interventions such as behavioural management or providing the young person with empowering strategies, implying that psychotropic pharmacotherapy should not be the first-line treatment. However, if assessment indicates that psychotropic medication is necessary, it can be of great benefit.

AB - The most important factor in deciding whether psychotropic medication should be prescribed is a meticulous assessment of the possible causes of the behavioural/psychiatric disturbance. This assessment should include a consideration of the possible roles of the epilepsy itself, treatment of the epilepsy, associated brain damage or dysfunction, reactions to the epilepsy and causes that are unrelated to the epilepsy or its treatment. If the epilepsy itself or antiepileptic drug treatment are responsible for the disorder then a review of antiepileptic medication is required. Contrary to popular myth, most psychotropic medications are not contraindicated in children with epilepsy. Treatment with methylphenidate, dexamfetamine, atomoxetine, clonidine or low-dose risperidone are unlikely to precipitate seizures. The selective serotonin reuptake inhibitors might protect against seizures but some of these are powerful enzyme inhibitors, implying that careful monitoring to avoid antiepileptic drug toxicity is recommended. In many cases, the appropriate approach will be through other interventions such as behavioural management or providing the young person with empowering strategies, implying that psychotropic pharmacotherapy should not be the first-line treatment. However, if assessment indicates that psychotropic medication is necessary, it can be of great benefit.

KW - Absence

KW - Anxiety

KW - CSWS

KW - Depression

KW - Postictal

UR - http://www.scopus.com/inward/record.url?scp=84975686859&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975686859&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84975686859

VL - 18

SP - S77-S86

JO - Epileptic Disorders

JF - Epileptic Disorders

SN - 1294-9361

ER -